VSTM has been the subject of a number of other research reports. Cantor Fitzgerald raised their price objective on Verastem from $3.00 to $6.00 and gave the company an “overweight” rating in a research report on Tuesday, March 3rd. HC Wainwright raised their price objective on Verastem from $2.50 to $2.75 and gave the company a “buy” rating in a research report on Monday, March 16th. ValuEngine upgraded Verastem from a “hold” rating to a “buy” rating in a research report on Thursday, March 12th. Finally, Zacks Investment Research lowered Verastem from a “buy” rating to a “hold” rating in a research report on Wednesday, January 1st. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Verastem presently has a consensus rating of “Buy” and a consensus price target of $5.95.
NASDAQ:VSTM traded up $0.21 on Thursday, reaching $2.49. 1,495,112 shares of the company’s stock traded hands, compared to its average volume of 3,342,669. The company has a quick ratio of 2.74, a current ratio of 2.84 and a debt-to-equity ratio of 14.93. The stock has a 50-day simple moving average of $2.25 and a 200-day simple moving average of $1.57. The firm has a market cap of $361.61 million, a PE ratio of -1.24 and a beta of 2.04. Verastem has a 12 month low of $0.83 and a 12 month high of $3.49.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning boosted its position in shares of Verastem by 26.9% during the fourth quarter. Creative Planning now owns 117,547 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 24,950 shares during the period. Aries Wealth Management raised its stake in shares of Verastem by 100.0% during the fourth quarter. Aries Wealth Management now owns 20,003 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10,000 shares in the last quarter. Samalin Investment Counsel LLC bought a new stake in shares of Verastem during the fourth quarter valued at approximately $118,000. Middleton & Co Inc MA bought a new stake in shares of Verastem during the fourth quarter valued at approximately $40,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Verastem during the fourth quarter valued at approximately $126,000. Institutional investors own 21.23% of the company’s stock.
Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Featured Story: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.